This page is part of the FHIR Specification (v1.4.0: STU 3 Ballot 3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4 R3 R2
Drug-drug interaction between prescription and medication statement
{ "resourceType": "DetectedIssue", "id": "ddi", "text": { "status": "generated", "div": "<div>\n <p><b>Severity: High</b> - Risk of internal bleeding</p>\n <p>Those who take acetaminophen along with the widely used blood-thinning drug warfarin may face the risk of serious internal bleeding. People on warfarin who take acetaminophen for at least seven days in a row should be closely watched for bleeding.</p>\n <ul>\n <li><a href=\"MedicationStatement/tylenol\">500 mg Acetaminophen tablet 1/day, PRN since 2010</a></li>\n <li><a href=\"MedicationOrder/warfarin\">Warfarin 1 MG TAB prescribed Jan. 5, 2014</a></li>\n </ul>\n <p>Mitigation: Jan 5, 2014 by Dr. Adam Careful: </p>\n <p>Asked patient to discontinue regular use of Tylenol and to consult with clinician if they need to resume to allow appropriate INR monitoring</p>\n </div>" }, "category": { "coding": [ { "system": "http://hl7.org/fhir/v3/ActCode", "code": "DRG", "display": "Drug Interaction Alert" } ] }, "severity": "high", "implicated": [ { "reference": "MedicationStatement/tylenol", "display": "500 mg Acetaminophen tablet 1/day, PRN since 2010" }, { "reference": "MedicationOrder/warfarin", "display": "Warfarin 1 MG TAB prescribed Jan. 5, 2014" } ], "detail": "Risk of internal bleeding. Those who take acetaminophen along with the widely used blood-thinning drug warfarin may face the risk of serious internal bleeding. People on warfarin who take acetaminophen for at least seven days in a row should be closely watched for bleeding.", "date": "2014-01-05", "author": { "reference": "Device/dsp" }, "mitigation": [ { "action": { "coding": [ { "system": "http://hl7.org/fhir/v3/ActCode", "code": "13", "display": "Stopped Concurrent Therapy" } ], "text": "Asked patient to discontinue regular use of Tylenol and to consult with clinician if they need to resume to allow appropriate INR monitoring" }, "date": "2014-01-05", "author": { "reference": "Practitioner/example", "display": "Dr. Adam Careful" } } ] }
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.